Bearing in mind the following facts: (1) localization of GPR55 receptors in the brain areas implicated in the pathophysiology of depression (Wu et al., 2013), (2) reduced GPR55 gene expression in the dorsolateral prefrontal cortex of suicide victims (Garcia-Gutierrez et al., 2018), and (3) anxiolytic-like effect of GPR55 receptor agonism (Rahimi et al., 2015; Shi et al., 2017), GPR55 receptors have drawn our attention as a potential target in the treatment of mood disorders. This evidence concerns the gene GPR55 and depressive disorder.